

LISTĂ DE LUCRĂRI

Candidat: Adela Simona Cernea

a) Teza de doctorat

Titlul: *Funcția beta celulară în diabetul zaharat nou diagnosticat*

Conducător de doctorat: Prof. dr. Minodora Dobreanu

Diploma de DOCTOR eliberată de MINISTERUL EDUCAȚIEI NAȚIONALE, nr. 20/21.01.2014

Calificativul: Excelent

b) Cărți de specialitate

De la ultima promovare:

1. **Cernea S**, Onișor D, Boeriu A. *Diabetul zaharat și patologiile cronice hepatice*. Editura University Press Târgu Mureș, 2022, 156 pg, ISBN 978-606-581-180-5, cod CNCIS 210.
2. **Cernea S** (editor). *Terapia medicală nutrițională în diabetul zaharat și alte boli metabolice*. Editura Casa Cărții de Știință Cluj Napoca, 2021, 284 pg, ISBN 978-606-17-1797-2, cod CNCIS 24.

Înainte de ultima promovare:

3. **Cernea S**. *Patogeneza diabetului zaharat*. Editura University Press Târgu Mureș, 2017, 325 pg, ISBN 978-973-169-502-0, cod CNCIS 210.
4. **Cernea S**. *Evaluarea pacientului cu diabet zaharat: ghid practic pentru medici de familie și rezidenți*. Editura University Press Târgu Mureș, 2014, 138 pg, ISBN 978-973-169-275-3, cod CNCIS 210.

c) Capitole în volume colective

De la ultima promovare:

1. **Cernea S**, Rus V. *Fructoza – prieten sau dușman*, în *Nutriția în prevenția și terapia bolilor cronice netransmisibile* (sub redacția Graur M (editor)), Editura Gr.T. Popa Iași, 2020, pg. 237-248, ISBN 978-606-544-690-8, cod CNCIS 229.
2. **Cernea S**, Cahn A, Raz I. *Glycemic targets and prevention of chronic complications*, în *Diabetes Epidemiology, Genetics, Pathogenesis, Diagnosis, Prevention, and Treatment* (sub redacția Enzo Bonora, Ralph A. DeFronzo), Editura Springer International Publishing, 2018, pg 421-450, ISBN 978-3-319-45014-8.

Înainte de ultima promovare:

3. Dobreanu M, **Cernea S**. *Metabolismul carbohidraților*, în *Biochimie clinică. Implicații practice* (sub redacția Dobreanu M), Editura University Press Târgu Mureș, 2015, pg 1-44 (volumul II), ISBN 978-973-169-357-6, cod CNCIS 210.
4. **Cernea S**, Nagar R, Bitton G, Raz I. *Insulin therapy and hypoglycemia- present and future*, în *Diabetes - Damages and Treatments* (sub redacția Everlon Cid Rigobelo), Editura InTech Croația, 2011, pg 161-182, ISBN 978-953-307-652-2.

5. Hâncu N, **Cernea S.** *Ficatul în diabetul zaharat, în Tratat de hepatologie* (sub redacția Grigorescu M), Editura Medicală Națională București, 2004, pg 971-978, ISBN 973-659-078-x, cod CNCS 167.

d) Articole publicate in extenso

(1) Articole în reviste cotate ISI, cu factor de impact

De la ultima promovare:

1. Onea CR, Erőss Á, Roiban AL, **Cernea S.** *The metabolic cont rol and laboratory evaluation in patients with type 2 diabetes during the COVID 19 pandemic and the impact of telemedicine: a single center experience.* Rev Rom Med Lab 2022. Ahead of print: DOI:10.2478/rrlm-2023-0002, ISSN:1841-6624, FI (2021): 0,493; autor corespondent; articol *original*.
2. **Cernea S**, Onișor D. *Screening and interventions to prevent nonalcoholic fatty liver disease/nonalcoholic steatohepatitis associated hepatocellular carcinoma.* World J Gastroenterol. Jan 14, 2023; 29(2): 286-309; Published online Jan 14, 2023 ahead of print. doi: 10.3748/wjg.v29.i2.286, ISSN: 1007-9327, FI (2021): 5,374; autor corespondent.
3. Manu P, Lăcătușu CM, Rogozea LM, **Cernea S.** *Pharmacological Management of Obesity: A Century of Expert Opinions in Cecil Textbook of Medicine.* Am J Ther. 2022; 29(4): e410-e424, doi: 10.1097/MJT.0000000000001524, ISSN: 1075-2765, FI (2021): 3,098.
4. **Cernea S**, Raz I. *Management of diabetic neuropathy.* Metabolism. 2021; 123:154867, doi: 10.1016/j.metabol.2021.154867, ISSN: 0026-0495, FI: 13,934; autor corespondent.
5. Manu P, Rogozea LM, **Cernea S.** *Pharmacological Management of Diabetes Mellitus: A Century of Expert Opinions in Cecil Textbook of Medicine.* Am J Ther. 2021; 28(4): e397-e410. doi: 10.1097/MJT.0000000000001401, ISSN: 1075-2765, FI: 3,098.
6. Buicu AL, **Cernea S**, Benedek I, Buicu CF, Benedek T. *Systemic Inflammation and COVID-19 Mortality in Patients with Major Noncommunicable Diseases: Chronic Coronary Syndromes, Diabetes and Obesity.* J Clin Med. 2021; 10(8): 1545, doi: 10.3390/jcm10081545, eISSN: 2077-0383, FI: 4,964; autor corespondent.
7. **Cernea S**, Raz I. *NAFLD in type 2 diabetes mellitus - still many challenging questions.* Diabetes Metab Res Rev. 2021; 37(2): e3386, doi: 10.1002/dmrr.3386, ISSN: 1520-7552, FI: 8,128; autor corespondent.
8. **Cernea S**, Dima L, Correll CU, Manu P. *Pharmacological Management of Glucose Dysregulation in Patients Treated with Second-Generation Antipsychotics.* Drugs. 2020; 80(17):1763-1781. doi: 10.1007/s40265-020-01393-x, ISSN: 0012-6667, FI: 9,546.
9. **Cernea S**, Both E, Fodor A. *The association of anthropometric parameters with markers of insulin and leptin secretion and resistance in type 2 diabetes mellitus.* Rev Rom Med Lab. 2020; 28(3): 299-314. doi: 10.2478/rrlm-2020-0028, ISSN:1841-6624. FI: 1,027, autor corespondent; articol *original*.

10. Crețu D, **Cernea S**, Onea CR, Pop RM. *Reproductive health in women with type 2 diabetes mellitus*. Hormones (Athens). 2020;19(3): 291-300. doi: 10.1007/s42000-020-00225-7, ISSN: 1109-3099, FI: 2,885.
11. Vonica CL, Farcas AD, Roman G, Mureșan AA, Fodor A, **Cernea S**, Georgescu CE. *Metabolomic biomarkers of polycystic ovary syndrome related-obesity: a review of the literature*. Rev Rom Med Lab. 2020; 28(3): 241-255. doi: 10.2478/rrlm-2020-0017, ISSN:1841-6624, FI: 1,027.
12. Rus VA, Chitu M, **Cernea S**, Benedek I, Hodas R, Zavate R, Nyulas T, Hintea M, Benedek T. *Altered nutritional status, inflammation and systemic vulnerability in patients with acute myocardial infarction undergoing percutaneous coronary revascularisation: A prospective study in a level 3 cardiac critical care unit*. Nutr Diet. 2020; 77: 212–222. doi: 10.1111/1747-0080.12536, ISSN: 1446-6368, FI: 2,333; articol original.
13. **Cernea S**, Raz I. *Insulin Therapy: Future Perspectives*. Am J Ther. 2020; 27(1): e121-e132. doi: 10.1097/MJT.0000000000001076, ISSN: 1075-2765, FI: 2,688; autor corespondent.
14. **Cernea S**, Both E, Huțanu A, Șular FL, Roiban AL. *Correlations of serum leptin and leptin resistance with depression and anxiety in patients with type 2 diabetes*. Psychiatry Clin Neurosci. 2019; 73 (12): 745–753. doi: 10.1111/pcn.12922, ISSN: 1440-1819, FI: 3,351; autor corespondent; articol original.
15. **Cernea S**, Roiban AL, Both E, Huțanu A. *Serum leptin and leptin resistance correlations with NAFLD in patients with type 2 diabetes*. Diabetes Metab Res Rev. 2018; 34: e3050. doi: 10.1002/dmrr.3050, ISSN: 1520-7552, FI: 4,758; autor corespondent; articol original.

Înainte de ultima promovare:

16. **Cernea S**, Cahn A, Raz I. *Pharmacological management of nonalcoholic fatty liver disease in type 2 diabetes*. Expert Rev Clin Pharmacol. 2017; 10: 535-547. doi: 10.1080/17512433.2017.1300059, ISSN 1751-2433, FI: 2,758; autor corespondent.
17. Cahn A, **Cernea S**, Raz I. *An update on DPP-4 inhibitors in the management of type 2 diabetes*. Expert Opin Emerg Drugs. 2016; 21: 409-419. doi: 10.1080/14728214.2016.1257608; ISSN 472-8214, FI: 3,062.
18. **Cernea S**, Șular FL, Huțanu A, Voidăzan S. *Markers of cognitive impairment in patients with type 2 diabetes*. Rev Rom Med Lab. 2016; 24(2): 161-176. doi: 10.1515/rrlm-2016-0023, ISSN 1841-6624, FI: 0,325; autor corespondent; articol original.
19. Cahn A, **Cernea S**, Raz I. *Outcome studies and safety as guide for decision making in treating patients with type 2 diabetes*. Rev Endocr Metab Disord. 2016; 17(1): 117-127. doi: 10.1007/s11154-016-9351-6, ISSN 1389-9155, FI: 4,817.
20. **Cernea S**, Cahn A, Raz I. *Saxagliptin for the treatment of diabetes - a focus on safety*. Expert Opin Drug Saf. 2016; 15: 697-707. doi: 10.1517/14740338.2016.1159675, ISSN 1474-0338, FI: 3,439.
21. **Cernea S**, Dobreanu M. *Diabetes and beta cell function: from mechanisms to evaluation and clinical implications*. Biochem Med (Zagreb). 2013; 23: 266-280. doi: 10.11613/bm.2013.033, ISSN 1330-0962, FI: 2,400; autor corespondent.

22. **Cernea S**, Huțanu A, Coroș L, Dobreanu M. *Assessment of beta cell function in subjects with newly diagnosed type 2 diabetes*. Rev Rom Med Lab. 2013; 21: 145-160. doi: 10.2478/rrlm-2013-0011, ISSN 1841-6624, FI: 0,171; autor corespondent; articol original.
23. Buzzetti R, **Cernea S**, Petrone A, Capizzi M, Spoletini M, Zampetti S, Guglielmi C, Venditti C, Pozzilli P. *C-peptide response and HLA genotypes in subjects with recent-onset type 1 diabetes following immunotherapy with DiaPep277: an exploratory study*. Diabetes. 2011, 60: 3067-3072. doi: 10.2337/db10-0560, ISSN 0012-1797, FI: 8,286; articol original.
24. **Cernea S**, Raz I. *Therapy in the early stage: incretins*. Diabetes Care. 2011; 34 Suppl 2: S264-S271. doi: 10.2337/dc11-s223, ISSN 0149-5992. FI: 8,087; autor corespondent.
25. **Cernea S**, Herold KC. *Monitoring of antigen-specific CD8 T cells in patients with type 1 diabetes treated with antiCD3 monoclonal antibodies*. Clin Immunol. 2010, 134: 121-129. doi: 10.1016/j.clim.2009.09.005, ISSN 1521-6616, FI: 3,932; articol original.
26. **Cernea S**, Dobreanu M, Raz I. *Prevention of type 1 diabetes: today and tomorrow*. Diabetes Metab Res Rev. 2010; 26: 602-605. doi: 10.1002/dmrr.1138, ISSN 1520-7552, FI: 3,094; autor corespondent.
27. **Cernea S**, Raz I, Herold KC, Hirshberg B, Roep RO, Schatz DA, Fleming GA, Pozzilli P, Little R, Schloot NC, Leslie D, Skyler JS, Palmer JP. *Challenges in developing endpoints in type 1 diabetes intervention studies*. Diabetes Metab Res Rev. 2009, 25: 694-704. doi: 10.1002/dmrr.1002, ISSN 1520-7552, FI: 2,762; autor corespondent.
28. **Cernea S**, Buzzetti R, Pozzilli P. *Beta cell protection and therapy for LADA*. Diabetes Care. 2009; 32 Suppl 2: S246-S252. doi: 10.2337/dc09-S317, ISSN 0149-5992. FI: 6,718.
29. **Cernea S**, Pozzilli P. *New potential treatments for protection of pancreatic B-cell function in type 1 diabetes*. Diabet Med. 2008; 25: 1259-1267. doi: 10.2337/diacare.28.6.1353, ISSN 0742-3071, FI: 3,172.
30. Witkowski P, Liu Z, **Cernea S**, Guo Q, Poumian-Ruiz E, Herold K, Hardy MA. *Validation of the scoring system for standardization of the pancreatic donor for islet isolation as used in a new islet isolation center*. Transplant Proc. 2006; 38: 3039-3040. doi: 10.1016/j.transproceed.2006.08.143, ISSN 0041-1345, FI: 0,962; articol original.
31. **Cernea S**, Raz I. *Noninjectable methods of insulin administration*. Drugs Today (Barc). 2006; 42: 405-424. doi: 10.1358/dot.2006.42.6.985632, ISSN 1699-3993. FI: 1,503.
32. **Cernea S**, Herold KC. *Drug insight: new immunomodulatory therapies in type 1 diabetes*. Nat Clin Pract Endocrinol Metab. 2006; 2: 89-98. doi: 10.1038/ncpendmet0082, ISSN 1759-5029, FI: 1,000.
33. **Cernea S**, Kidron M, Wohlgelernter J, Raz I. *Dose-response relationship of an oral insulin spray in six patients with type 1 diabetes: a single-center, randomized, single-blind, 5-way crossover study*. Clin Ther. 2005; 27: 1562-1570. doi: 10.1016/j.clinthera.2005.10.007, ISSN 0149-2918, FI: 3,030; articol original.
34. Witkowski P, Liu Z, Guo Q, Poumian-Ruiz E, **Cernea S**, Herold K, Hardy MA. *Two-layer method in short-term pancreas preservation for successful islet isolation*. Transplant

- Proc. 2005; 37: 3398-3401. doi: 10.1016/j.transproceed.2005.09.050, ISSN 0041-1345, FI: 0,799; articol *original*.
35. **Cernea S**, Kidron M, Wohlgelernter J, Modi P, Raz I. *Dose-response relationship of oral insulin in healthy subjects*. Diabetes Care. 2005; 28: 1353-1357. doi: 10.2337/diacare.28.6.1353, ISSN 0149-5992, FI: 7,844; articol *original*.
 36. Raz I, Eldor R, **Cernea S**, Shafir E. *Diabetes: insulin resistance and derangements in lipid metabolism. Cure through intervention in fat transport and storage*. Diabetes Metab Res Rev. 2005; 21: 3-14. doi: 10.1002/dmrr.493, ISSN 1520-7552, FI: 2,453.
 37. **Cernea S**, Kidron M, Wohlgelernter J, Modi P, Raz I. *Comparison of pharmacokinetic and pharmacodynamic properties of single-dose oral insulin spray and subcutaneous insulin injection in healthy subjects using the euglycemic clamp technique*. Clin Ther. 2004; 26: 2084- 2091. doi: 10.1016/j.clinthera.2004.12.001, ISSN 0149-2918, FI: 3,009; articol *original*.
 38. **Cernea S**, Hâncu N, Raz I. *Diet and coronary heart disease in diabetes*. Acta Diabetol. 2003; 40 Suppl 2: S389–S400. doi: 10.1007/s00592-003-0125-8, ISSN 0940-5429, FI: 0,811; autor corespondent.

(2) Articole în reviste cotate ISI, cu factor de impact (editorial/comentariu editorial)

De la ultima promovare:

1. Raz I, **Cernea S**, Cahn A. *SGLT2 inhibitors for primary prevention of cardiovascular events*. J Diabetes. 2020; 12(1): 5-7. doi: 10.1111/1753-0407.13004, ISSN: 1753-0393. FI: 4,006.
2. Cahn A, **Cernea S**, Raz I. *The SONAR study—is there a future for endothelin receptor antagonists in diabetic kidney disease?* Ann Transl Med. 2019; 7(Suppl 8): S330. doi: 10.21037/atm.2019.09.117, ISSN: 2305-5839. FI: 3,297.

Înainte de ultima promovare:

3. **Cernea S**, Cahn A. *Diabetes mellitus: in search of an improved classification and treatment algorithm*. Rev Rom Med Lab. 2016; 24(1): 9-20. doi: 10.1515/rrlm-2016-0001, ISSN 1841-6624, FI: 0,325; autor corespondent.

(3) Articole în reviste cotate ISI, fără factor de impact (editorial)

De la ultima promovare:

1. **Cernea S**. *Nutritional Status and Clinical Outcomes of Cardiac Patients in Acute Settings*. Journal of Cardiovascular Emergencies. 2018; 4: 5-7, doi: 10.2478/jce-2018-0007, ISSN: 2457-5518; autor corespondent.

(4) Articole în reviste indexate BDI/B+

De la ultima promovare:

1. **Cernea S**, Ruța F. *Intermittent fasting for the management of NAFLD: Is there enough evidence?* Acta Marisiensis Seria Medica 2023; 69(1): 179-186; Ahead of print: DOI: 10.2478/amma 2023-0001, ISSN 2068-3324; indexat DOAJ (Directory of Open Access Journals) (<https://doaj.org/>), EBSCO (<https://www.ebsco.com/>); autor corespondent.

2. Duka K, Onea CR, **Cernea S**. *Factors Associated with Diabetes-Related Distress in Patients with Type 2 Diabetes Mellitus*. Journal of Interdisciplinary Medicine. 2021; 6(3):138-145; doi: 10.2478/jim-2021-0027, ISSN 2501-5974; indexat DOAJ (Directory of Open Access Journals) (<https://doaj.org/>), EBSCO (<https://www.ebsco.com/>); autor corespondent; articol *original*.
3. Onea CR, Mate B, **Cernea S**. *Reproductive health and metabolic parameters in women with type 2 diabetes*. Journal of Interdisciplinary Medicine. 2020; 5(1): 10-15. doi: 10.2478/jim-2020-0003, ISSN 2501-5974; indexat DOAJ (Directory of Open Access Journals) (<https://doaj.org/>), Scopus (<https://www.scopus.com/home.uri>); autor corespondent; articol *original*.
4. **Cernea S**, Vultur F. *Metode și abordări eficiente în prevenția retinopatiei diabetice* (Effective methods and approaches in the prevention of diabetic retinopathy). Romanian Medical Journal. 2019; vol LXVI (suppl 3): 10-15. doi: 10.37897/RMJ.2019.S3.3, ISSN: 1220-5478, indexat DOAJ (Directory of Open Access Journals) (<https://doaj.org/>), EBSCO (<https://www.ebsco.com/>);
5. **Cernea S**, Roiban AL, Both E. *Malnutrition and metabolic changes in patients with type 2 diabetes*. Journal of Interdisciplinary Medicine. 2018; 3(3): 160-167. doi: 10.2478/jim-2018-0030, ISSN 2501-5974; indexat DOAJ (Directory of Open Access Journals) (<https://doaj.org/>), EBSCO (<https://www.ebsco.com/>); autor corespondent; articol *original*.

Înainte de ultima promovare:

6. **Cernea S**, Blendea C, Roiban AL, Benedek T. *Cardio-renal correlations and epicardial adipose tissue in patients with type 2 diabetes*. Journal of Interdisciplinary Medicine. 2017; 2(4):312-319. doi: 10.1515/jim-2017-0085, ISSN 2501-5974; indexat DOAJ (Directory of Open Access Journals) (<https://doaj.org/>), EBSCO (<https://www.ebsco.com/>); autor corespondent; articol *original*.
7. **Cernea S**. *Heart Failure and Chronic Kidney Disease in Type 2 Diabetes*. Journal of Interdisciplinary Medicine. 2016; 1(3): 252-258. doi: 10.1515/jim-2016-0066, ISSN 2501-5974; indexat DOAJ (Directory of Open Access Journals) (<https://doaj.org/>), EBSCO (<https://www.ebsco.com/>); autor corespondent.
8. **Cernea S**, Zoltai C, Berbecilă D, Șular FL. *Prevalence of Depression, Anxiety and Cognitive Impairment in Patients with Type 2 Diabetes from the Central Part of Romania*. Acta Medica Marisiensis. 2016; 62(2): 209-216. doi: 10.1515/amma-2016-0014, ISSN 2068-3324; indexat DOAJ (Directory of Open Access Journals) (<https://doaj.org/>), EBSCO (<https://www.ebsco.com/>); autor corespondent; articol *original*.
9. **Cernea S**. *The role of incretin therapy at different stages of diabetes*. Rev Diabet Stud 2011, 8: 323-328. doi: 10.1900/RDS.2011.8.323, ISSN 1613-6071; indexed in PubMed/Medline (<https://pubmed.ncbi.nlm.nih.gov/>), EBSCO (<https://www.ebsco.com/>); autor corespondent.

10. **Cernea S.** *Buccal insulin spray for prandial therapy of Type 1 and Type 2 diabetes.* Diabetes Management 2012, 2: 47-54, doi: 10.2217/DMT.11.71, ISSN 1758-1907; indexat EMBASE (<https://www.embase.com/landing?status=yellow>), EMCare, Open J Gate (<https://jgateplus.com/home/>); autor corespondent.
11. **Cernea S.** *Perspective imunoterapeutice în diabetul zaharat tip 1.* Med Mod 2008, XV (2): 58-63, ISSN 2360-2473; revistă B+, cod CNCIS 475, poziția 230; autor corespondent.

e) Articole publicate în rezumat în reviste și volumele unor manifestări științifice, cu ISBN/ISSN:

De la ultima promovare:

1. **Cernea S,** Roiban AL, Both E, Huțanu A. *Correlations of sleep quality with serum leptin and leptin resistance in type 2 diabetes.* Al 2-lea Congres Național al Asociației de Medicină de Laborator cu Participare Internațională. București, Romania, Mai 2018; Rev Rom Med Lab 2018; 26: S118-119; ISSN: 1841-6624.

f) Alte lucrări și contribuții științifice in extenso

(1) Articole publicate sub formă de cărți cu ISBN (colecție de articole)

De la ultima promovare:

1. **Cernea S,** Onișor D. *Boala ficatului gras non-alcoholic și diabetul zaharat.* În Diabet zaharat 2022, Viața Medicală: Medihub Media, București 2022; pg 100-104, ISBN: 978-606-95339-4-9, 978-606-95260-5-7.
2. **Cernea S,** Moțățăianu A. *Neuropatia diabetică autonomă cardiacă în diabetul zaharat – aspecte clinice.* În Diabet zaharat 2020, Viața Medicală: Medihub Media, București 2020; pg 35--37, ISBN: 978-606-94854-0-8, 978-606-92727-6-3.

(2) Alte lucrări (necuantificate în grilă)

De la ultima promovare:

1. **Cernea S.** *Diagnosticul și clasificarea tulburărilor metabolismului glucidic.* În Ghid de management al diabetului zaharat. Elaborat de Societatea Română de Diabet, Nutriție și Boli Metabolice (Președinte: Prof. univ. dr. Romulus Timar) Și Federația Română de Diabet, Nutriție și Boli Metabolice (Președinte: Prof. univ. dr. Gabriela Roman), 2021, pg 9-17.

Înainte de ultima promovare:

2. **Cernea S,** Barchetta I, Pozzilli P, Giordano C, Mantione L. *Opinioni a confronto: L'immuno-intervento nel diabete tipo 1 alla diagnosi e nei soggetti a rischio (Opinions in comparison: the immune intervention in type 1 diabetes at diagnosis and in subjects at risk).* Il Diabete 2008, 20: 143-159.
3. **Coca V,** **Cernea S,** Hâncu N. *Disfuncția endotelială din diabetul zaharat.* InfoMedica 2004, 11: 4-11, cod CNCIS 307.